Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 3/20 | 0.45 |
| ▸ | CTSD | P07339 | 4/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 8/20 | 0.43 |
| ▸ | MMP3 | P08254 | 8/20 | 0.43 |
| ▸ | MMP1 | P03956 | 6/20 | 0.43 |
| ▸ | MMP7 | P09237 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16507825 | 0.94 | APLNR (0.53) | PSMB5APLNRGLP1RF2CTSD | |
| SCHEMBL16507912 | 0.92 | APLNR (0.52) | PSMB5APLNRGLP1RF2 | |
| SCHEMBL16508102 | 0.92 | F2 (0.46) | PSMB5APLNRGLP1RF2 | |
| SCHEMBL16507772 | 0.91 | APLNR (0.51) | APLNRGLP1RF2 | |
| SCHEMBL16507773 | 0.91 | OPRM1 (0.49) | PSMB5APLNRGLP1RF2 | |
| SCHEMBL16507962 | 0.91 | APLNR (0.52) | PSMB5APLNRGLP1RF2 | |
| SCHEMBL16508132 | 0.88 | NPY5R (0.48) | PSMB5APLNRF2MMP1 | |
| SCHEMBL16507916 | 0.87 | APLNR (0.52) | PSMB5APLNRGLP1RF2 | |
| SCHEMBL16508053 | 0.87 | APLNR (0.52) | PSMB5APLNRGLP1RF2 | |
| SCHEMBL16507751 | 0.86 | NPY5R (0.47) | APLNRGLP1RF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | PSMB5 928/4885APLNR 222/4885GLP1R 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.